Introduced: 2006 (gained FDA approval Oct. The two are made by Pfizer and Merck, respectively. The FDA has approved two biosimilars to Remicade: Inflectra, in Apr. Treats: CrohnвЂ™s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. Introduced: 1998 (granted FDA approval Aug. At launch, Basaglar was priced at 15% less than Lantus. The FDA approved the biosimilar Basaglar, made by Eli Lilly, in Dec. $75 per pen (annual dosing varies widely one pen may last from less than a day to more than a week) 20, 2000 Solostar is specifically an automatic pen-style delivery mechanism)Д¬urrently costs: Approx. Introduced: 2000 (granted FDA approval Apr. Lantus Solostar (insulin glargine): $5.7 billion

That legal action is expected to delay any biosimilar to Enbrel from hitting the market until 2018 at the earliest, and possibly not until 2029.

However, as with the generic version of Humira, this drug is being held up because Novartis is being sued for alleged patent infringement by Amgen. 2016, the FDA approved a biosimilar drug (Erelzi) made by Novartis. Treats: First introduced as to treat rheumatoid arthritis now also prescribed for psoriatic arthritis, juvenile ideopathic arthritis, ankylosing spondylitis, and plaque psoriasis.Д¬urrently costs: $49,762 вЂ“ $62,202 per year Introduced: 1998 (granted FDA approval Nov. Generica drug company Mylan, after entering a deal with Gilead, has launched a generic equivalent in India, but it is not currently approved or for sale in the U.S. Harvoni is the specific combination of two drugs, ledipasvir and sofosbuvir. Introduced: 2014 (granted FDA approval Oct. Harvoni (ledipasvir/sofosbuvir): $10 billion Due to that ongoing litigation Amgen executives have said not to expect their product to ship until 2018 at the earliest. However, AbbVie sued Amgen over it, claiming patent infringement. The FDA approved a biosimilar drug, Amjevita, from Amgen in late 2016. Treats: First introduced to treat rheumatoid arthritis now also prescribed for psoriatic arthritis, juvenile ideopathic arthritis, ankylosing spondylitis, plaque psoriasis, ulcerative colitis, and CrohnвЂ™s disease.Д¬urrently costs:В $49,752 вЂ“ $58,044 per year Introduced: 2003 (granted FDA approval Dec. In terms of the ailments treated by these pharmaceutical money-makers, rheumatoid arthritis shows up most frequently, followed by diabetes. Only three of these drugs have generic versions available some of them have generic versions that could be released but are being held up by lawsuits. Combined, they represent more than $60 billion a year in sales. Still, they show a clear pattern of how many billions of dollars the top blockbuster drugs are bringing in.Д«elow is some more information on the ten biggest earners in the U.S. The figures, Axios notes, are pure gross figures, and so donвЂ™t reflect what individuals or their insurers are paying, and donвЂ™t include any negotiations, discounts, rebates, coupons, or promotions. in 2016, based on data from the QuintilesIMS Institute. earn more than $60 billion a year for their manufacturers, with the biggest money-maker topping $13 billion per year in sales on its own.ДЄxios compiled a handy chart of the top 20 top-selling drugs in the U.S. And now a new report shows that the top-selling brand-name prescription drugs in the U.S. Americans spend hundreds of billions on prescription medications every year, with that figure projected to keep growing. ItвЂ™s no secret that big pharma is big business.

Bcs class 1 drugs more profitable